Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation